Click on the studies below to learn 
more information at

A clinical study evaluating safety and efficacy of elacestrant in various combinations (alpelisib, everolimus, palbociclib, capivasertib, ribociclib or abemaciclib) in patients with metastatic breast cancer.

A clinical study evaluating elacestrant in combination with abemaciclib in patients with brain metastasis from ER+, HER2- breast cancer. 

A clinical study evaluating elacestrant in patients with CDK4/6 inhibitor-naive ER+, HER2- metastatic breast cancer.

The information above is not intended for promotional or marketing purposes. The safety and efficacy of investigational uses of marketed products have not been established and marketing approval has not been granted by regulatory authorities.

© 2024 - Stemline Therapeutics, Inc., a Menarini Group Company. All rights reserved. 
06/2024 ELA-05336-v2